Cognitive Impairment in Frail Hypertensive Elderly Patients: Role of Hyperglycemia

Area of Science:

• Gerontology and Cardiovascular Research
• Neuroscience and Endocrinology

Background:

• Endothelial dysfunction is a hallmark of hypertension, a major risk factor for cognitive decline in aging populations.
• Hyperglycemia impairs endothelial function and predicts cardiovascular events, irrespective of diabetes status.
• Frail hypertensive older adults represent a vulnerable group where hyperglycemia may exacerbate cognitive impairment.

Purpose of the Study:

• To investigate the impact of high glucose and metformin on brain microvascular endothelial cells (ECs) in vitro.
• To assess the effects of hyperglycemia and metformin on cognitive function in frail hypertensive patients.

Main Methods:

• In vitro testing of metformin's effects on high-glucose-induced cell death, permeability, and reactive oxygen species in human brain microvascular ECs.
• Clinical study involving frail hypertensive patients, evaluating Montreal Cognitive Assessment (MoCA) scores based on glycemic status and metformin use.
• Comparison of MoCA scores between hyperglycemic patients treated with metformin versus those treated with insulin.

Main Results:

• A significant correlation was observed between MoCA scores and glycemia levels.
• Hyperglycemic patients treated with metformin demonstrated significantly higher MoCA scores (18.32 ± 3.9) compared to those treated with insulin (14.94 ± 3.8; p < 0.001).
• In vitro experiments confirmed metformin's protective effects on human brain microvascular ECs against high-glucose damage.

Conclusions:

• Hyperglycemia exacerbates cognitive impairment in frail, hypertensive older adults.
• Metformin may offer neuroprotective benefits by improving endothelial function and cognitive outcomes in this patient population.
• This study provides novel insights into the relationship between glycemia, cognitive function, and endothelial health in frail hypertensive individuals.